Business Context and Reporting Period
This Form 8-K filing by Dermata Therapeutics, Inc. (DRMA) reports a corporate governance event dated February 23, 2026. The company is an emerging growth company incorporated in Delaware with principal executive offices in San Diego, California.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a change in board composition and contains no financial data.
Material Changes
The material change reported is the resignation of Mary Fisher from the Board of Directors. Her resignation is effective March 31, 2026, and will reduce the Board size from eight to seven members. The filing explicitly states this departure is not due to any disagreement with the Company regarding operations, policies, or practices.
Outlook, Risks, and Management Commentary
Management commentary indicates that Ms. Fisher's resignation is necessitated by her employer's recent acquisition, which no longer permits her to serve on the Company's Board. No guidance, future outlook, specific risks, or unusual items are disclosed in this filing.
Key Facts for Investor Verification
- Resignation of Director Mary Fisher is effective March 31, 2026.
- The Board of Directors will decrease in size from eight to seven members.
- The resignation is driven by external employment constraints, not internal company disputes.
- No financial performance data is included in this specific filing.